Bryan Close - Novacyt Chief Officer
| ALNOV Stock | EUR 0.56 0.02 3.45% |
Insider
Bryan Close is Chief Officer of Novacyt
| Phone | 33 1 39 46 51 04 |
| Web | https://www.novacyt.com |
Novacyt Management Efficiency
The company has return on total asset (ROA) of 0.0145 % which means that it generated a profit of $0.0145 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0198) %, meaning that it generated substantial loss on money invested by shareholders. Novacyt's management efficiency ratios could be used to measure how well Novacyt manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Joachim Reichelt | Eurofins Scientific SE | N/A | |
| Heiko Imhl | Sartorius Stedim Biotech | N/A | |
| Giles Pelissier | SEB SA | N/A | |
| Laurent Lebras | Eurofins Scientific SE | N/A | |
| Rajesh Saigal | Eurofins Scientific SE | N/A | |
| Timothy Oostdyk | Eurofins Scientific SE | N/A | |
| Isabelle Posth | SEB SA | N/A | |
| John Mackay | Sartorius Stedim Biotech | 61 | |
| Valerie Leylde | Biomerieux SA | N/A | |
| Gilles Martin | Eurofins Scientific SE | 60 | |
| Yvoine Remy | Eurofins Scientific SE | N/A | |
| Sylvain Morgeau | Biomerieux SA | N/A | |
| Gabriel Julia | Eurofins Scientific SE | N/A | |
| Cathy Pianon | SEB SA | N/A | |
| Sandra Hoeylaerts | Eurofins Scientific SE | N/A | |
| Benedikt Orzelek | Sartorius Stedim Biotech | N/A | |
| Pierre Boulud | Biomerieux SA | 52 | |
| Martin Zouhar | SEB SA | N/A | |
| Olivier Guitard | Sartorius Stedim Biotech | N/A | |
| Frederic Beseme | Biomerieux SA | 67 | |
| Alexandre Merieux | Biomerieux SA | 49 | |
Management Performance
| Return On Equity | -0.0198 | |||
| Return On Asset | 0.0145 |
Novacyt Leadership Team
Elected by the shareholders, the Novacyt's board of directors comprises two types of representatives: Novacyt inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novacyt. The board's role is to monitor Novacyt's management team and ensure that shareholders' interests are well served. Novacyt's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novacyt's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steve Gibson, Member of the Executive Team, Group Financial Controller | ||
| David Franks, Chief Officer | ||
| Grald Ulrich, Chief Devel | ||
| James McCarthy, Acting CFO | ||
| Wendy Karban, Member of the Executive Team, Group Human Resource Manager | ||
| Bryan Close, Chief Officer | ||
| Paul Oladimeji, Group RD |
Novacyt Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Novacyt a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0198 | |||
| Return On Asset | 0.0145 | |||
| Profit Margin | (0.1) % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | (48.03 M) | |||
| Shares Outstanding | 70.63 M | |||
| Shares Owned By Insiders | 3.49 % | |||
| Shares Owned By Institutions | 1.60 % | |||
| Price To Earning | (1.71) X | |||
| Price To Book | 0.43 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Novacyt Stock Analysis
When running Novacyt's price analysis, check to measure Novacyt's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novacyt is operating at the current time. Most of Novacyt's value examination focuses on studying past and present price action to predict the probability of Novacyt's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novacyt's price. Additionally, you may evaluate how the addition of Novacyt to your portfolios can decrease your overall portfolio volatility.